Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis

Main Article Content

Boni Elewski
Alan Menter
Jeffrey Crowley
Stephen Tyring
Yang Zhao
Simon Lowry
Stephen Rozzo
Alan Mendelsohn
Jeffrey Parno
Kenneth Gordon

Keywords

psoriasis, tildrakizumab

Abstract

Abstract not available.

 

Disclosures: Study sponsored by SUN PHARMA.

 

Copyright SKIN 2018

Article Sidebar

Poster PDF
Published
Feb 23, 2018
DOI https://doi.org/10.25251/skin.2.supp.22

Article Details

How to Cite
Elewski, B., Menter, A., Crowley, J., Tyring, S., Zhao, Y., Lowry, S., Rozzo, S., Mendelsohn, A., Parno, J., & Gordon, K. (2018). Sustained and Improved Efficacy of Tildrakizumab from Week 28 to Week 52 in Treating Moderate-to-Severe Plaque Psoriasis. SKIN The Journal of Cutaneous Medicine, 2(S1), S22. https://doi.org/10.25251/skin.2.supp.22
Issue
Vol. 2 (2018): Supplemental Issue: Scientific Posters Presented at 2018 Winter Clinical Dermatology Conference®-Hawaii
Section
Psoriasis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors transfer copyright to the publisher as part of the journal publishing agreement.

All reprints are subject to the reprint policy.